Fezakinumab

From Infogalactic: the planetary knowledge core

Jump to: navigation, search

Fezakinumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IL13
Identifiers
CAS Number	1007106-86-6^N
ATC code	none
UNII	0S77U25XZ3^Y
Chemical data
Formula	C₆₄₀₈H₉₈₇₃N₁₇₀₆O₂₀₁₆S₄₄
Molecular mass	143.87 kg/mol

^NY (what is this?) (verify)

Fezakinumab is a human monoclonal antibody against interleukin-22,^[1] designed for the treatment of psoriasis and rheumatoid arthritis.^[2]

Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis, ^[3] but data was not released. Development was discontinued in August 2011.

References

↑ Lua error in package.lua at line 80: module 'strict' not found.
↑ page 6; http://www.pfizer.com/files/research/pipeline/2011_0228/pipeline_2011_0228.pdf
↑ http://lmt.projectsinknowledge.com/Activity/index.cfm?showfile=b&jn=2016&sj=2016.05&sc=2016.05.4

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	immunosuppression: Abrilumab Adalimumab Anifrolumab Atorolimumab Belimumab Brodalumab Carlumab Dupilumab Durvalumab Eldelumab Fresolimumab Golimumab Lerdelimumab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oxelumab§ Placulumab Sarilumab Sifalimumab Tabalumab Ulocuplumab Varlilumab immune activation: Ipilimumab Nivolumab Pembrolizumab Tremelimumab Urelumab other: Bertilimumab Zanolimumab
Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric ("-lixi-")	Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized ("-lizu-")	immunosuppressive: Aselizumab Apolizumab Benralizumab^† Cedelizumab Certolizumab pegol Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Itolizumab Lampalizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab PRO 140^† Reslizumab Rontalizumab Rovelizumab Ruplizumab Quilizumab Samalizumab Siplizumab Talizumab Teplizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab TGN1412^§ non-immunosuppressive: Ibalizumab^†
Chimeric + humanized ("-lixizu-")	Otelixizumab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Clazakizumab Enokizumab Gevokizumab Ixekizumab Lebrikizumab Olokizumab Perakizumab Tildrakizumab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

v t e Index of the immune system
Description	Physiology cells autoantigens autoantibodies complement surface antigens IG receptors
Disease	Allergies Immunodeficiency Immunoproliferative immunoglobulin disorders Hypersensitivity and autoimmune disorders Neoplasms and cancer
Treatment	Procedures Drugs antihistamines immunostimulants immunosuppressants monoclonal antibodies

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://infogalactic.com/w/index.php?title=Fezakinumab&oldid=707383386"

Categories:

Hidden categories:

Fezakinumab

References

Navigation menu

Personal tools

Namespaces

Variants

Views

More

Search

Navigation

Tools